CoChat

Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis

Jennings, Lisa · 2009 · Thrombosis and Haemostasis

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Abstract

Summary: Platelets are central mediators of haemostasis at sites of vascular injury, but they also mediate pathologic thrombosis. Activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion, promoting atherothrombotic disease. They also interact with endothelial cells and leukocytes to promote inflammation, which contributes to atherosclerosis. Multiple pathways contribute to platelet activation, and current oral antiplatelet therapy with aspirin and a P2Y12 adenosine diphosphate (ADP) receptor antagonist target the thromboxane A2 and ADP pathways, respectively. Both can diminish activation by other factors, but the extent of their effects depends upon the agonist, agonist strength, and platelet reactivity status. Although these agents have demonstrated significant clinical benefit, residual morbidity and mortality remain high. Neither agent is effective in inhibiting thrombin, the most potent platelet activator. This lack of comprehensive inhibition of platelet function allows continued thrombus formation and exposes patients to risk for recurrent thrombotic events. Moreover, bleeding risk is a substantial limitation of antiplatelet therapy, because these agents target platelet activation pathways critical for both protective haemostasis and pathologic thrombosis. Novel antiplatelet therapies that provide more complete inhibition of platelet activation without increasing bleeding risk could considerably decrease residual risk for ischemic events. Inhibition of the protease-activated receptor (PAR)-1 platelet activation pathway stimulated by thrombin is a novel, emerging approach to achieve more comprehensive inhibition of platelet activation when used in combination with current oral antiplatelet agents. PAR-1 inhibition is not expected to increase bleeding risk, as this pathway does not interfere with haemostasis.

Overview

Integrity signals

Registry

Crossref · 10.1160/th09-03-0192

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 436

Metadata

Authors
Jennings, L.
Affiliations
University of Tennessee Health Science Center (US)
Corresponding author
Jennings, Lisa
Venue
Thrombosis and Haemostasis
Published
2009
Volume
102
Issue
08
Pages
248-257
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2071461268
Cited by
436
References
85
Citations by year
2026: 5 · 2025: 21 · 2024: 26 · 2023: 26 · 2022: 25 · 2021: 25 · 2020: 23 · 2019: 27 · 2018: 22 · 2017: 21 · 2016: 25 · 2015: 30 · 2014: 35 · 2013: 33 · 2012: 26
FWCI
20.16
Type
journal article
Language
en
Open access
closed
Locations
  • Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
platelet activation, atherothrombosis, antiplatelet therapy, thrombin, protease-activated receptor 1, thromboxane A2, P2Y12 receptor, aspirin, bleeding risk, thrombus formation
MeSH terms
Animals, Blood Coagulation, Blood Platelets, Hemostasis, Humans, Inflammation, Leukocytes, Models, Biological, Platelet Aggregation Inhibitors, Thrombosis, Signal Transduction, Platelet Activation, Receptor, PAR-1, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.